Download PDF
Semin Respir Crit Care Med 2024; 45(01): 088-101
DOI: 10.1055/s-0043-1776914
Review Article

Chronic Pulmonary Aspergillosis: Clinical Presentation and Management

Terry J. Evans
1   Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Mahosot Hospital, Vientiane, Lao PDR
,
AbdulAzeez Lawal
2   National Aspergillosis Centre, Wythenshawe Hospital, Manchester University Foundation Trust, Manchester, United Kingdom
,
Chris Kosmidis
2   National Aspergillosis Centre, Wythenshawe Hospital, Manchester University Foundation Trust, Manchester, United Kingdom
3   Manchester Fungal Infection Group, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
,
David W. Denning
3   Manchester Fungal Infection Group, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Chronic pulmonary aspergillosis (CPA) refers to a number of clinical syndromes resulting from the presence and local proliferation of Aspergillus organisms in the lungs of patients with chronic lung disease. CPA is more common than was realized two decades ago. Recognition remains poor, despite recent studies from many countries highlighting the high prevalence in at-risk populations. In low- and middle-income countries, CPA may be misdiagnosed and treated as tuberculosis (TB). In addition, CPA may develop following successful TB treatment. The coronavirus disease pandemic has resulted in significant disruption to provision of TB care, likely leading to more extensive lung damage, which could increase the risk for CPA.

Although CPA refers to various syndromes, the classic presentation is that of chronic cavitary pulmonary aspergillosis, which manifests as one or more progressive cavities with or without a fungal ball, accompanied by systemic and respiratory symptoms for at least 3 months. Diagnosis relies on Aspergillus immunoglobulin G in serum, as sputum culture lacks sensitivity. Differential diagnosis includes mycobacterial infection, bacterial lung abscess or necrotizing pneumonia, lung cancer, and endemic fungi.

The aim of antifungal treatment in CPA is to improve symptoms and quality of life, and to halt progression, and possibly reverse radiological changes. Current recommendations suggest treatment for 6 months, although in practice many patients remain on long-term treatment. Improvement may manifest as weight gain and improvement of symptoms such as productive cough, hemoptysis, and fatigue. Surgical management should be considered in cases of diagnostic uncertainty, in significant hemoptysis, and when there is concern for lack of response to therapy. Itraconazole and voriconazole are the first-line azoles, with more experience now accumulating with posaconazole and isavuconazole. Side effects are frequent and careful monitoring including therapeutic drug monitoring is essential. Intravenous antifungals such as echinocandins and amphotericin B are used in cases of azole intolerance or resistance, which often develop on treatment. Relapse is seen after completion of antifungal therapy in around 20% of cases, mostly in bilateral, high-burden disease.

Several research priorities have been identified, including characterization of immune defects and genetic variants linked to CPA, pathogenetic mechanisms of Aspergillus adaptation in the lung environment, the contribution of non-fumigatus Aspergillus species, and the role of new antifungal agents, immunotherapy, and combination therapy.

Keywords

Aspergillus fumigatus - azole resistance - hemoptysis - lobectomy - micafungin


Publication History

Article published online:
28 December 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 World Health Organization. WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022. Accessed August 1, 2023 at: https://www.who.int/publications/i/item/9789240060241
    Google Scholar
  • 2 Bongomin F, Gago S, Oladele RO, Denning DW. Global and national prevalence of fungal diseases – estimate precision. J Fungi (Basel) 2017; 3: E57
    CrossrefPubMedGoogle Scholar
  • 3 Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 2011; 37 (04) 865-872
    CrossrefPubMedGoogle Scholar
  • 4 Denning DW, Cadranel J, Beigelman-Aubry C. et al; European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016; 47 (01) 45-68
    CrossrefPubMedGoogle Scholar
  • 5 Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax 2015; 70 (03) 270-277
    CrossrefPubMedGoogle Scholar
  • 6 Muldoon EG, Sharman A, Page I, Bishop P, Denning DW. Aspergillus nodules; another presentation of Chronic Pulmonary Aspergillosis. BMC Pulm Med 2016; 16 (01) 123
    CrossrefPubMedGoogle Scholar
  • 7 Kang N, Park J, Jhun BW. Clinical characteristics and treatment outcomes of pathologically confirmed Aspergillus nodules. J Clin Med 2020; 9 (07) 2185
    CrossrefPubMedGoogle Scholar
  • 8 Page ID, Byanyima R, Hosmane S. et al. Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. Eur Respir J 2019; 53 (03) 1801184
    CrossrefPubMedGoogle Scholar
  • 9 Prasad A, Agarwal K, Deepak D, Atwal SS. Pulmonary aspergillosis: what CT can offer before it is too late!. J Clin Diagn Res 2016; 10 (04) TE01-TE05
    PubMedGoogle Scholar
  • 10 Nguyen NTB, Le Ngoc H, Nguyen NV. et al. Chronic pulmonary aspergillosis situation among post tuberculosis patients in Vietnam: an observational study. J Fungi (Basel) 2021; 7 (07) 532
    CrossrefPubMedGoogle Scholar
  • 11 Godet C, Laurent F, Bergeron A. et al; ACHROSCAN Study Group. CT imaging assessment of response to treatment in chronic pulmonary aspergillosis. Chest 2016; 150 (01) 139-147
    CrossrefPubMedGoogle Scholar
  • 12 Gazzoni FF, Severo LC, Marchiori E. et al. Pulmonary diseases with imaging findings mimicking aspergilloma. Lung 2014; 192 (03) 347-357
    CrossrefPubMedGoogle Scholar
  • 13 Sharma S, Dubey SK, Kumar N, Sundriyal D. ‘Monod’ and ‘air crescent’ sign in aspergilloma. BMJ Case Rep 2013; 2013: bcr2013200936
    CrossrefPubMedGoogle Scholar
  • 14 Yang C-T, Pan S-W. The Monod sign of aspergilloma in simple chest radiographs. QJM 2022; 115 (04) 247-248
    CrossrefPubMedGoogle Scholar
  • 15 Yudin A. Air crescent, air sickle sign or Monod sign, rattle sign. In: Metaphorical Signs in Computed Tomography of Chest and Abdomen. Cham: Springer; 2023
    CrossrefGoogle Scholar
  • 16 Kosmidis C, Newton P, Muldoon EG, Denning DW. Chronic fibrosing pulmonary aspergillosis: a cause of ‘destroyed lung’ syndrome. Infect Dis (Lond) 2017; 49 (04) 296-301
    CrossrefPubMedGoogle Scholar
  • 17 Volpe Chaves CE, do Valle Leone de Oliveira SM, Venturini J. et al. Accuracy of serological tests for diagnosis of chronic pulmonary aspergillosis: a systematic review and meta-analysis. PLoS ONE 2020; 15 (03) e0222738
    CrossrefPubMedGoogle Scholar
  • 18 Anan K, Kataoka Y, Okabayashi S, Yamamoto R, Namkoong H, Yamamoto Y. Diagnostic accuracy of Aspergillus-specific antibodies for chronic pulmonary aspergillosis: a systematic review and meta-analysis. Mycoses 2021; 64 (07) 701-715
    CrossrefPubMedGoogle Scholar
  • 19 Stucky Hunter E, Richardson MD, Denning DW. Evaluation of LD Bio Aspergillus ICT lateral flow assay for IgG and IgM antibody detection in chronic pulmonary aspergillosis. J Clin Microbiol 2019; 57 (09) e00538-e19
    CrossrefPubMedGoogle Scholar
  • 20 Ray A, Chowdhury M, Sachdev J. et al. Efficacy of LD Bio Aspergillus ICT lateral flow assay for serodiagnosis of chronic pulmonary aspergillosis. J Fungi (Basel) 2022; 8 (04) 400
    CrossrefPubMedGoogle Scholar
  • 21 Singh S, Choudhary H, Agnihotri S. et al. LDBio Aspergillus immunochromatographic test lateral flow assay for IgG/IgM antibody detection in chronic pulmonary aspergillosis: single-centre evaluation and meta-analysis. Indian J Med Microbiol 2022; 40 (02) 204-210
    CrossrefPubMedGoogle Scholar
  • 22 Hunter ES, Wilopo B, Richardson MD, Kosmidis C, Denning DW. Effect of patient immunodeficiencies on the diagnostic performance of serological assays to detect Aspergillus-specific antibodies in chronic pulmonary aspergillosis. Respir Med 2021; 178: 106290
    CrossrefPubMedGoogle Scholar
  • 23 Shinfuku K, Suzuki J, Takeda K. et al. Validity of Platelia Aspergillus IgG and Aspergillus precipitin test to distinguish pulmonary aspergillosis from colonization. Microbiol Spectr 2023; 11 (01) e0343522
    CrossrefPubMedGoogle Scholar
  • 24 Bongomin F, Garcez T, Denning DW. Impact of high baseline Aspergillus-specific IgG levels on weight and quality-of-life outcomes of patients with chronic pulmonary aspergillosis. Med Mycol 2020; 58 (07) 1000-1004
    CrossrefPubMedGoogle Scholar
  • 25 Bongomin F, Out A, Harris C, Foden P, Kosmidis C, Denning DW. Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy. Clin Infect Pract 2020; 5: 100015
    CrossrefPubMedGoogle Scholar
  • 26 Setianingrum F, Rautemaa-Richardson R, Shah R, Denning DW. Clinical outcomes of patients with chronic pulmonary aspergillosis managed surgically. Eur J Cardiothorac Surg 2020; 58 (05) 997-1003
    CrossrefPubMedGoogle Scholar
  • 27 Sehgal IS, Dhooria S, Choudhary H. et al. Monitoring treatment response in chronic pulmonary aspergillosis: role of clinical, spirometric and immunological markers. Clin Microbiol Infect 2019; 25 (09) 1157.e1-1157.e7
    CrossrefPubMedGoogle Scholar
  • 28 Izumikawa K, Yamamoto Y, Mihara T. et al. Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis. Med Mycol 2012; 50 (08) 811-817
    CrossrefPubMedGoogle Scholar
  • 29 Sehgal IS, Dhooria S, Choudhary H. et al. Utility of serum and bronchoalveolar lavage fluid galactomannan in diagnosis of chronic pulmonary aspergillosis. J Clin Microbiol 2019; 57 (03) e01821-e18
    CrossrefPubMedGoogle Scholar
  • 30 Sehgal IS, Dhooria S, Choudhary H. et al. Efficiency of A. fumigatus-specific IgG and galactomannan testing in the diagnosis of simple aspergilloma. Mycoses 2019; 62 (12) 1108-1115
    CrossrefPubMedGoogle Scholar
  • 31 Fayemiwo S, Moore CB, Foden P, Denning DW, Richardson MD. Comparative performance of Aspergillus galactomannan ELISA and PCR in sputum from patients with ABPA and CPA. J Microbiol Methods 2017; 140: 32-39
    CrossrefPubMedGoogle Scholar
  • 32 Nuh A, Ramadan N, Shah A, Armstrong-James D. Sputum galactomannan has utility in the diagnosis of chronic pulmonary aspergillosis. J Fungi (Basel) 2022; 8 (02) 188
    CrossrefPubMedGoogle Scholar
  • 33 Vergidis P, Moore CB, Novak-Frazer L. et al. High-volume culture and quantitative real-time PCR for the detection of Aspergillus in sputum. Clin Microbiol Infect 2020; 26 (07) 935-940
    CrossrefPubMedGoogle Scholar
  • 34 Severo LC, Geyer GR, Porto NdaS, Wagner MB, Londero AT. Pulmonary Aspergillus niger intracavitary colonization. Report of 23 cases and a review of the literature. Rev Iberoam Micol 1997; 14 (03) 104-110
    PubMedGoogle Scholar
  • 35 Moazam S, Eades CP, Muldoon EG, Moore CB, Richardson MD, Rautemaa-Richardson R. Positive Aspergillus PCR as a marker of azole resistance or sub-therapeutic antifungal therapy in patients with chronic pulmonary aspergillosis. Mycoses 2020; 63 (04) 376-381
    CrossrefPubMedGoogle Scholar
  • 36 Singh A, Sharma B, Mahto KK, Meis JF, Chowdhary A. High-frequency direct detection of triazole resistance in Aspergillus fumigatus from patients with chronic pulmonary fungal diseases in India. J Fungi (Basel) 2020; 6 (02) 67
    CrossrefPubMedGoogle Scholar
  • 37 Novak-Frazer L, Anees-Hill SP, Hassan D. et al. Deciphering Aspergillus fumigatus cyp51A-mediated triazole resistance by pyrosequencing of respiratory specimens. J Antimicrob Chemother 2020; 75 (12) 3501-3509
    CrossrefPubMedGoogle Scholar
  • 38 Denning DW, Cole DC, Ray A. New estimation of the prevalence of chronic pulmonary aspergillosis (CPA) related to pulmonary TB - a revised burden for India. IJID Reg 2022; 6: 7-14
    CrossrefPubMedGoogle Scholar
  • 39 World Health Organization. Global Tuberculosis Report 2122. COVID-19 and TB. Accessed August 1, 2023 at: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022/covid-19-and-tb
    PubMed
  • 40 Chaurasia S, Thimmappa M, Chowdhury S. Case report: Chronic cavitatory pulmonary aspergillosis after COVID-19. Am J Trop Med Hyg 2021; 106 (01) 105-107
    CrossrefPubMedGoogle Scholar
  • 41 Razafindrasoa ZA, Ravahatra K, Tiaray HM. et al. COVID-19 complicated with chronic necrotizing pulmonary aspergillosis and aspergilloma progressing to fibrosing aspergillosis: a case report. Clin Case Rep 2022; 10 (05) e05814
    CrossrefPubMedGoogle Scholar
  • 42 Swain S, Ray A, Sarda R. et al. COVID-19-associated subacute invasive pulmonary aspergillosis. Mycoses 2022; 65 (01) 57-64
    CrossrefPubMedGoogle Scholar
  • 43 Meghji J, Mortimer K, Agusti A. et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet 2021; 397 (10277): 928-940
    CrossrefPubMedGoogle Scholar
  • 44 Jhun BW, Moon SM, Jeon K. et al. Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study. Eur Respir J 2020; 55 (01) 1900798
    CrossrefPubMedGoogle Scholar
  • 45 Namusobya M, Bongomin F, Mukisa J. et al. Chronic pulmonary aspergillosis in patients with active pulmonary tuberculosis with persisting symptoms in Uganda. Mycoses 2022; 65 (06) 625-634
    CrossrefPubMedGoogle Scholar
  • 46 Toychiev A, Belotserkovets V, Ignat'ev N, Madrakhimov S, Shaislamova M, Osipova S. Prevalence of chronic pulmonary aspergillosis and the antifungal drug resistance of Aspergillus spp. in pulmonary tuberculosis patients in Uzbekistan. Trop Doct 2022; 52 (04) 515-521
    CrossrefPubMedGoogle Scholar
  • 47 Ocansey BK, Otoo B, Gbadamosi H. et al. Importance of Aspergillus-specific antibody screening for diagnosis of chronic pulmonary aspergillosis after tuberculosis treatment: a prospective follow-up study in Ghana. J Fungi (Basel) 2022; 9 (01) 26
    CrossrefPubMedGoogle Scholar
  • 48 Lakoh S, Kamara JB, Orefuwa E. et al. Prevalence and predictors of Aspergillus seropositivity and chronic pulmonary aspergillosis in an urban tertiary hospital in Sierra Leone: a cross-sectional study. PLoS Negl Trop Dis 2023; 17 (07) e0011284
    CrossrefPubMedGoogle Scholar
  • 49 Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I. NIHR RESPIRE Global Respiratory Health Unit. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med 2022; 10 (05) 447-458
    CrossrefPubMedGoogle Scholar
  • 50 Okoi C, Anderson STB, Antonio M, Mulwa SN, Gehre F, Adetifa IMO. Non-tuberculous Mycobacteria isolated from pulmonary samples in sub-Saharan Africa - a systematic review and meta analyses. Sci Rep 2017; 7 (01) 12002
    CrossrefPubMedGoogle Scholar
  • 51 Lai C-C, Hsueh P-R. Diseases caused by nontuberculous mycobacteria in Asia. Future Microbiol 2014; 9 (01) 93-106
    CrossrefPubMedGoogle Scholar
  • 52 Denning DW, Page ID, Chakaya J. et al. Case definition of chronic pulmonary aspergillosis in resource-constrained settings. Emerg Infect Dis 2018; 24 (08) e171312
    CrossrefPubMedGoogle Scholar
  • 53 Sousa C, Marchiori E, Youssef A. et al. Chest imaging in systemic endemic mycoses. J Fungi (Basel) 2022; 8 (11) 1132
    CrossrefPubMedGoogle Scholar
  • 54 Baker J, Kosmidis C, Rozaliyani A, Wahyuningsih R, Denning DW. Chronic pulmonary histoplasmosis – a scoping literature review. Open Forum Infect Dis 2020; 7 (05) ofaa119
    CrossrefPubMedGoogle Scholar
  • 55 Li X, Hu W, Wan Q. et al. Non-HIV talaromycosis: radiological and clinical analysis. Medicine (Baltimore) 2020; 99 (10) e19185
    CrossrefPubMedGoogle Scholar
  • 56 Ekeng BE, Davies AA, Osaigbovo II, Warris A, Oladele RO, Denning DW. Pulmonary and extrapulmonary manifestations of fungal infections misdiagnosed as tuberculosis: the need for prompt diagnosis and management. J Fungi (Basel) 2022; 8 (05) 460
    CrossrefPubMedGoogle Scholar
  • 57 Ashraf N, Kubat RC, Poplin V. et al. Re-drawing the maps for endemic mycoses. Mycopathologia 2020; 185 (05) 843-865
    CrossrefPubMedGoogle Scholar
  • 58 Chakrabarti A, Slavin MA. Endemic fungal infections in the Asia-Pacific region. Med Mycol 2011; 49 (04) 337-344
    CrossrefPubMedGoogle Scholar
  • 59 Baker J, Setianingrum F, Wahyuningsih R, Denning DW. Mapping histoplasmosis in South East Asia - implications for diagnosis in AIDS. Emerg Microbes Infect 2019; 8 (01) 1139-1145
    CrossrefPubMedGoogle Scholar
  • 60 Rozaliyani A, Setianingrum F. The review of Histoplasmosis endemicity and current status in Asia. In: Histoplasma and Histoplasmosis. Bongomin F, ed. 2020
    PubMedGoogle Scholar
  • 61 Lauar ID, Nascimento VAM, Soares JEP. et al. Esporotricose pulmonar em paciente imunocompetente: relato de caso. Revista Médica De Minas Gerais 2021; 31: e-31415
    CrossrefPubMedGoogle Scholar
  • 62 Sharma B, Sharma AK, Sharma U. Sporotrichosis: a comprehensive review on recent drug-based therapeutics and management. Curr Dermatol Rep 2022; 11 (02) 110-119
    CrossrefPubMedGoogle Scholar
  • 63 Sun HY, Chen MY, Hsiao CF, Hsieh SM, Hung CC, Chang SC. Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated with highly active anti-retroviral therapy. Clin Microbiol Infect 2006; 12 (04) 381-388
    CrossrefPubMedGoogle Scholar
  • 64 Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344 (8915): 110-113
    CrossrefPubMedGoogle Scholar
  • 65 Iqbal N, Irfan M, Jabeen K, Kazmi MM, Tariq MU. Chronic pulmonary mucormycosis: an emerging fungal infection in diabetes mellitus. J Thorac Dis 2017; 9 (02) E121-E125
    CrossrefPubMedGoogle Scholar
  • 66 Severo LC, Kaemmerer A, Camargo JJ, Porto NS. Actinomycotic intracavitary lung colonization. Mycopathologia 1989; 108 (01) 1-4
    CrossrefPubMedGoogle Scholar
  • 67 Yan X, Li M, Jiang M, Zou LQ, Luo F, Jiang Y. Clinical characteristics of 45 patients with invasive pulmonary aspergillosis: retrospective analysis of 1711 lung cancer cases. Cancer 2009; 115 (21) 5018-5025
    CrossrefPubMedGoogle Scholar
  • 68 Marukawa M, Taniguchi A, Kimura G. et al; OKAYAMA Respiratory Disease Study Group (ORDSG). Solitary pulmonary nodules caused by Mycobacterium avium complex. Respir Investig 2019; 57 (06) 566-573
    CrossrefPubMedGoogle Scholar
  • 69 Chong VF, Fan YF. The radiology of melioidosis. Australas Radiol 1996; 40 (03) 244-249
    CrossrefPubMedGoogle Scholar
  • 70 Garjito TA, Mujiyanto M, Sudomo M. Echinococcosis: past and present situation in southeast. Asia 2019
    PubMed
  • 71 Karshima SN, Ahmed MI, Adamu NB, Magaji AA, Zakariah M, Mohammed K. Africa-wide meta-analysis on the prevalence and distribution of human cystic echinococcosis and canine Echinococcus granulosus infections. Parasit Vectors 2022; 15 (01) 357
    CrossrefPubMedGoogle Scholar
  • 72 Farid S, Mohamed S, Devbhandari M. et al. Results of surgery for chronic pulmonary Aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence–a National Centre's experience. J Cardiothorac Surg 2013; 8: 180
    CrossrefPubMedGoogle Scholar
  • 73 Regnard J-F, Icard P, Nicolosi M. et al. Aspergilloma: a series of 89 surgical cases. Ann Thorac Surg 2000; 69 (03) 898-903
    CrossrefPubMedGoogle Scholar
  • 74 Kim YT, Kang MC, Sung SW, Kim JH. Good long-term outcomes after surgical treatment of simple and complex pulmonary aspergilloma. Ann Thorac Surg 2005; 79 (01) 294-298
    CrossrefPubMedGoogle Scholar
  • 75 Maghrabi F, Denning DW. The management of chronic pulmonary aspergillosis: The UK National Aspergillosis Centre Approach. Curr Fungal Infect Rep 2017; 11 (04) 242-251
    CrossrefPubMedGoogle Scholar
  • 76 Chen QK, Chen C, Chen XF, Jiang GN. Video-assisted thoracic surgery for pulmonary aspergilloma: a safe and effective procedure. Ann Thorac Surg 2014; 97 (01) 218-223
    CrossrefPubMedGoogle Scholar
  • 77 Kumar A, Asaf BB, Puri HV. et al. Video-assisted thoracoscopic surgery for pulmonary aspergilloma. Lung India 2017; 34 (04) 318-323
    CrossrefPubMedGoogle Scholar
  • 78 Zheng S, Li X, Hu B, Li H. Is adjuvant antifungal therapy after video-assisted thoracic surgery for pulmonary aspergilloma necessary?. J Thorac Dis 2018; 10 (11) 6060-6065
    CrossrefPubMedGoogle Scholar
  • 79 Keskin H, Dirol H, Bozkurt N. Pulmonary aspergilloma management: 5 years of experience from a tertiary hospital. Kardiochir Torakochirurgia Pol 2022; 19 (04) 194-198
    PubMedGoogle Scholar
  • 80 Yuan P, Cao JL, Huang S. et al. Sublobar resection for pulmonary aspergilloma: a safe alternative to lobectomy. Ann Thorac Surg 2017; 103 (06) 1788-1794
    CrossrefPubMedGoogle Scholar
  • 81 Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 2013; 56 (05) 559-570
    CrossrefPubMedGoogle Scholar
  • 82 Sehgal IS, Dhooria S, Muthu V. et al. Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India. Lancet Infect Dis 2022; 22 (07) 1052-1061
    CrossrefPubMedGoogle Scholar
  • 83 Sehgal IS, Dhooria S, Prasad KT. et al. Anti-fungal agents in the treatment of chronic pulmonary aspergillosis: systematic review and a network meta-analysis. Mycoses 2021; 64 (09) 1053-1061
    CrossrefPubMedGoogle Scholar
  • 84 Tashiro M, Takazono T, Saijo T. et al. Selection of oral antifungals for initial maintenance therapy in chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis 2020; 70 (05) 835-842
    PubMedGoogle Scholar
  • 85 Al-Shair K, Atherton GT, Harris C, Ratcliffe L, Newton PJ, Denning DW. Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis 2013; 57 (06) 828-835
    CrossrefPubMedGoogle Scholar
  • 86 Bongomin F, Harris C, Hayes G, Kosmidis C, Denning DW. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis. PLoS ONE 2018; 13 (04) e0193732
    CrossrefPubMedGoogle Scholar
  • 87 Baxter CG, Marshall A, Roberts M, Felton TW, Denning DW. Peripheral neuropathy in patients on long-term triazole antifungal therapy. J Antimicrob Chemother 2011; 66 (09) 2136-2139
    CrossrefPubMedGoogle Scholar
  • 88 Kosmidis C, Rodriguez-Goncer I, Rautemaa-Richardson R, Richardson MD, Moore CB, Denning DW. Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis. J Antimicrob Chemother 2019; 74 (04) 1056-1061
    CrossrefPubMedGoogle Scholar
  • 89 Kosmidis C, Otu A, Moore CB, Richardson MD, Rautemaa-Richardson R. Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis. Antimicrob Agents Chemother 2020; 65 (01) e01511-e01520
    CrossrefPubMedGoogle Scholar
  • 90 Howard SJ, Pasqualotto AC, Anderson MJ. et al. Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis. Mycoses 2013; 56 (04) 434-441
    CrossrefPubMedGoogle Scholar
  • 91 Denning DW, Park S, Lass-Florl C. et al. High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52 (09) 1123-1129
    CrossrefPubMedGoogle Scholar
  • 92 Takeda K, Suzuki J, Watanabe A. et al. High detection rate of azole-resistant Aspergillus fumigatus after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance. Med Mycol 2021; 59 (04) 327-334
    CrossrefPubMedGoogle Scholar
  • 93 van der Torre MH, Novak-Frazer L, Rautemaa-Richardson R. Detecting azole-antifungal resistance in Aspergillus fumigatus by pyrosequencing. J Fungi (Basel) 2020; 6 (01) 12
    CrossrefPubMedGoogle Scholar
  • 94 Rogers TR, Verweij PE, Castanheira M, Dannaoui E, White PL, Arendrup MC. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications. J Antimicrob Chemother 2022; 77 (08) 2053-2073
    CrossrefPubMedGoogle Scholar
  • 95 Kohno S, Izumikawa K, Ogawa K. et al; Japan Chronic Pulmonary Aspergillosis Study Group (JCPASG). Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 2010; 61 (05) 410-418
    CrossrefPubMedGoogle Scholar
  • 96 Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011; 71 (01) 11-41
    CrossrefPubMedGoogle Scholar
  • 97 Niazi-Ali S, Atherton GT, Walczak M, Denning DW. Drug-drug interaction database for safe prescribing of systemic antifungal agents. Ther Adv Infect Dis 2021; 8: 20 499361211010605
    PubMedGoogle Scholar
  • 98 Izumikawa K, Ohtsu Y, Kawabata M. et al. Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Med Mycol 2007; 45 (03) 273-278
    CrossrefPubMedGoogle Scholar
  • 99 Kohno S, Izumikawa K, Yoshida M. et al. A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis 2013; 32 (03) 387-397
    CrossrefPubMedGoogle Scholar
  • 100 Bongomin F, Asio LG, Olum R, Denning DW. Intravenous therapy for chronic pulmonary aspergillosis: a systematic review and meta-analysis. Mycoses 2020; 63 (09) 921-927
    CrossrefPubMedGoogle Scholar
  • 101 Otu AA, Bongomin F, Bazaz R, Harris C, Denning DW, Kosmidis C. Micafungin may be safely administered as outpatient parenteral antimicrobial therapy for chronic pulmonary aspergillosis. Mycoses 2019; 62 (02) 152-156
    CrossrefPubMedGoogle Scholar
  • 102 Keir GJ, Garfield B, Hansell DM. et al. Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis. Thorax 2014; 69 (03) 287-288
    CrossrefPubMedGoogle Scholar
  • 103 Kohno S, Izumikawa K, Ogawa K. et al. Intravenous liposomal amphotericin B versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. Acta Med Nagasaki 2017; 61 (04) 167-176
    PubMedGoogle Scholar
  • 104 Haro-Reyes T, Díaz-Peralta L, Galván-Hernández A, Rodríguez-López A, Rodríguez-Fragoso L, Ortega-Blake I. Polyene antibiotics physical chemistry and their effect on lipid membranes; impacting biological processes and medical applications. Membranes (Basel) 2022; 12 (07) 681
    CrossrefPubMedGoogle Scholar
  • 105 Rodrigues CF, Henriques M. Liposomal and deoxycholate amphotericin B formulations: effectiveness against biofilm infections of Candida spp. Pathogens 2017; 6 (04) 62
    CrossrefPubMedGoogle Scholar
  • 106 Newton PJ, Harris C, Morris J, Denning DW. Impact of liposomal amphotericin B therapy on chronic pulmonary aspergillosis. J Infect 2016; 73 (05) 485-495
    CrossrefPubMedGoogle Scholar
  • 107 Rae N, Kenny C, Muldoon EG. Can intravenous antifungal therapy be safely used in the outpatient parenteral antimicrobial therapy (OPAT) setting?. Mycoses 2019; 62 (03) 196-203
    CrossrefPubMedGoogle Scholar
  • 108 Kokkonouzis I, Athanasopoulos I, Doulgerakis N. et al. Fatal hemoptysis due to chronic cavitary pulmonary aspergillosis complicated by nontuberculous mycobacterial tuberculosis. Case Rep Infect Dis 2011; 2011: 837146
    PubMedGoogle Scholar
  • 109 Betancourt BY, Garofoli AC, Sandhu JS, Boma N, Sy AM. Pulmonary aspergillosis presenting with recurrent haemoptysis. BMJ Case Rep 2015; 2015: bcr2015211249
    CrossrefPubMedGoogle Scholar
  • 110 Koch A, Schanne DH, Günther G, Aebersold DM, Elicin O. Stereotactic body radiotherapy for recurrent hemoptysis due to chronic pulmonary aspergillosis: a case report and systematic review of the literature. Strahlenther Onkol 2023; 199 (02) 192-200
    CrossrefPubMedGoogle Scholar
  • 111 Prutsky G, Domecq JP, Salazar CA, Accinelli R. Antifibrinolytic therapy to reduce haemoptysis from any cause. Cochrane Database Syst Rev 2016; 11 (11) CD008711
    PubMedGoogle Scholar
  • 112 Chen LF, Wang TC, Lin TY. et al. Does tranexamic acid reduce risk of mortality on patients with hemoptysis?: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021; 100 (20) e25898
    CrossrefPubMedGoogle Scholar
  • 113 Tsai YS, Hsu LW, Wu MS, Chen KH, Kang YN. Effects of tranexamic acid on hemoptysis: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig 2020; 40 (09) 789-797
    CrossrefPubMedGoogle Scholar
  • 114 Moen CA, Burrell A, Dunning J. Does tranexamic acid stop haemoptysis?. Interact Cardiovasc Thorac Surg 2013; 17 (06) 991-994
    CrossrefPubMedGoogle Scholar
  • 115 Alexander GR. A retrospective review comparing the treatment outcomes of emergency lung resection for massive haemoptysis with and without preoperative bronchial artery embolization. Eur J Cardiothorac Surg 2014; 45 (02) 251-255
    CrossrefPubMedGoogle Scholar
  • 116 Walsh TJ, Anaissie EJ, Denning DW. et al; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46 (03) 327-360
    CrossrefPubMedGoogle Scholar
  • 117 Shin B, Koh WJ, Shin SW. et al. Outcomes of bronchial artery embolization for life-threatening hemoptysis in patients with chronic pulmonary aspergillosis. PLoS ONE 2016; 11 (12) e0168373
    CrossrefPubMedGoogle Scholar
  • 118 Sapienza LG, Gomes MJ, Maliska C, Norberg AN. Hemoptysis due to fungus ball after tuberculosis: a series of 21 cases treated with hemostatic radiotherapy. BMC Infect Dis 2015; 15: 546
    CrossrefPubMedGoogle Scholar
  • 119 Samuelian JM, Attia AA, Jensen CA, Monjazeb AM, Blackstock AW. Treatment of hemoptysis associated with aspergilloma using external beam radiotherapy: a case report and literature review. Pract Radiat Oncol 2011; 1 (04) 279-281
    CrossrefPubMedGoogle Scholar
  • 120 Bastin DJ, Arifin AJ, Yaremko BP. External-beam radiation therapy for Aspergilloma-associated hemoptysis. Appl Radiat Oncol 2020; 9 (01) 40-42
    CrossrefPubMedGoogle Scholar
  • 121 Nam HS, Jeon K, Um SW. et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis 2010; 14 (06) e479-e482
    CrossrefPubMedGoogle Scholar
  • 122 Nakamoto K, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis. Intern Med 2013; 52 (07) 727-734
    CrossrefPubMedGoogle Scholar
  • 123 Ohba H, Miwa S, Shirai M. et al. Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med 2012; 106 (05) 724-729
    CrossrefPubMedGoogle Scholar
  • 124 Camara B, Reymond E, Saint-Raymond C. et al; Grenoble Aspergillus Committee. Characteristics and outcomes of chronic pulmonary aspergillosis: a retrospective analysis of a tertiary hospital registry. Clin Respir J 2015; 9 (01) 65-73
    CrossrefPubMedGoogle Scholar
  • 125 Lowes D, Al-Shair K, Newton PJ. et al. Predictors of mortality in chronic pulmonary aspergillosis. Eur Respir J 2017; 49 (02) 1601062
    CrossrefPubMedGoogle Scholar
  • 126 Li Z, Denning DW. The impact of corticosteroids on the outcome of fungal disease: a systematic review and meta-analysis. Curr Fungal Infect Rep 2023; 17 (01) 54-70
    CrossrefPubMedGoogle Scholar
  • 127 Bongomin F, Harris C, Foden P, Kosmidis C, Denning DW. Innate and adaptive immune defects in chronic pulmonary aspergillosis. J Fungi (Basel) 2017; 3 (02) 26
    CrossrefPubMedGoogle Scholar
  • 128 Koyama K, Ohshima N, Suzuki J. et al. Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles. J Infect Chemother 2014; 20 (06) 375-379
    CrossrefPubMedGoogle Scholar
  • 129 Pasqualotto AC, Denning DW. Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. Int J Antimicrob Agents 2007; 30 (01) 93-94
    CrossrefPubMedGoogle Scholar
  • 130 Sehgal IS, Vinay K, Dhooria S. et al. Efficacy of generic forms of itraconazole capsule in treating subjects with chronic pulmonary aspergillosis. Mycoses 2023; 66 (07) 576-584
    CrossrefPubMedGoogle Scholar
  • 131 Godet C, Alastruey-Izquierdo A, Flick H. et al; CPAnet. A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention. J Antimicrob Chemother 2018; 73 (02) 280-286
    CrossrefPubMedGoogle Scholar